Logo image of OMGA

OMEGA THERAPEUTICS INC (OMGA) Stock Fundamental Analysis

USA - NASDAQ:OMGA - US68217N1054 - Common Stock

0.1426 USD
-0.02 (-10.82%)
Last: 2/24/2025, 8:00:02 PM
0.11 USD
-0.03 (-22.86%)
After Hours: 2/24/2025, 8:00:02 PM
Fundamental Rating

2

Overall OMGA gets a fundamental rating of 2 out of 10. We evaluated OMGA against 536 industry peers in the Biotechnology industry. OMGA may be in some trouble as it scores bad on both profitability and health. OMGA is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year OMGA has reported negative net income.
OMGA had a negative operating cash flow in the past year.
In the past 5 years OMGA always reported negative net income.
In the past 5 years OMGA always reported negative operating cash flow.
OMGA Yearly Net Income VS EBIT VS OCF VS FCFOMGA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 -20M -40M -60M -80M -100M

1.2 Ratios

Looking at the Return On Assets, with a value of -47.86%, OMGA is in line with its industry, outperforming 48.17% of the companies in the same industry.
OMGA has a worse Return On Equity (-633.21%) than 80.98% of its industry peers.
Industry RankSector Rank
ROA -47.86%
ROE -633.21%
ROIC N/A
ROA(3y)-49.09%
ROA(5y)-109.27%
ROE(3y)-99.62%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
OMGA Yearly ROA, ROE, ROICOMGA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 0 100 -100 -200 -300

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for OMGA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
OMGA Yearly Profit, Operating, Gross MarginsOMGA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 -1K -2K -3K -4K

More info and screens

1

2. Health

2.1 Basic Checks

OMGA does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, OMGA has more shares outstanding
OMGA has a better debt/assets ratio than last year.
OMGA Yearly Shares OutstandingOMGA Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M
OMGA Yearly Total Debt VS Total AssetsOMGA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 50M 100M 150M 200M

2.2 Solvency

OMGA has an Altman-Z score of -4.95. This is a bad value and indicates that OMGA is not financially healthy and even has some risk of bankruptcy.
OMGA has a Altman-Z score of -4.95. This is in the lower half of the industry: OMGA underperforms 60.73% of its industry peers.
A Debt/Equity ratio of 1.00 is on the high side and indicates that OMGA has dependencies on debt financing.
The Debt to Equity ratio of OMGA (1.00) is worse than 78.53% of its industry peers.
Industry RankSector Rank
Debt/Equity 1
Debt/FCF N/A
Altman-Z -4.95
ROIC/WACCN/A
WACC9.59%
OMGA Yearly LT Debt VS Equity VS FCFOMGA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 100M 200M

2.3 Liquidity

A Current Ratio of 1.61 indicates that OMGA should not have too much problems paying its short term obligations.
OMGA has a Current ratio of 1.61. This is amonst the worse of the industry: OMGA underperforms 80.80% of its industry peers.
OMGA has a Quick Ratio of 1.61. This is a normal value and indicates that OMGA is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of OMGA (1.61) is worse than 79.76% of its industry peers.
Industry RankSector Rank
Current Ratio 1.61
Quick Ratio 1.61
OMGA Yearly Current Assets VS Current LiabilitesOMGA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 50M 100M 150M 200M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 36.06% over the past year.
Looking at the last year, OMGA shows a very strong growth in Revenue. The Revenue has grown by 184.04%.
EPS 1Y (TTM)36.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%25%
Revenue 1Y (TTM)184.04%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%214.32%

3.2 Future

The Earnings Per Share is expected to grow by 23.60% on average over the next years. This is a very strong growth
OMGA is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 150.92% yearly.
EPS Next Y34.35%
EPS Next 2Y24.8%
EPS Next 3Y20.55%
EPS Next 5Y23.6%
Revenue Next Year233.18%
Revenue Next 2Y29.68%
Revenue Next 3Y37.19%
Revenue Next 5Y150.92%

3.3 Evolution

OMGA Yearly Revenue VS EstimatesOMGA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M
OMGA Yearly EPS VS EstimatesOMGA Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 2 -2 4 6

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

OMGA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for OMGA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
OMGA Price Earnings VS Forward Price EarningsOMGA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
OMGA Per share dataOMGA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1

4.3 Compensation for Growth

OMGA's earnings are expected to grow with 20.55% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y24.8%
EPS Next 3Y20.55%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for OMGA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

OMEGA THERAPEUTICS INC

NASDAQ:OMGA (2/24/2025, 8:00:02 PM)

After market: 0.11 -0.03 (-22.86%)

0.1426

-0.02 (-10.82%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-06 2025-03-06/amc
Earnings (Next)N/A N/A
Inst Owners81.36%
Inst Owner Change-24.83%
Ins Owners1.4%
Ins Owner Change0%
Market Cap7.90M
Analysts82.86
Price Target13.26 (9198.74%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)6.6%
Min EPS beat(2)-6.31%
Max EPS beat(2)19.51%
EPS beat(4)2
Avg EPS beat(4)6.61%
Min EPS beat(4)-6.31%
Max EPS beat(4)19.51%
EPS beat(8)5
Avg EPS beat(8)8.26%
EPS beat(12)8
Avg EPS beat(12)10.33%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)113.47%
Min Revenue beat(2)106.48%
Max Revenue beat(2)120.46%
Revenue beat(4)4
Avg Revenue beat(4)84.74%
Min Revenue beat(4)41.91%
Max Revenue beat(4)120.46%
Revenue beat(8)8
Avg Revenue beat(8)95.37%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)40.54%
PT rev (3m)40.54%
EPS NQ rev (1m)0%
EPS NQ rev (3m)15.75%
EPS NY rev (1m)0%
EPS NY rev (3m)2.37%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-4.71%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.03%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.98
P/FCF N/A
P/OCF N/A
P/B 0.68
P/tB 0.68
EV/EBITDA N/A
EPS(TTM)-1.33
EYN/A
EPS(NY)-0.8
Fwd EYN/A
FCF(TTM)-1.04
FCFYN/A
OCF(TTM)-1
OCFYN/A
SpS0.15
BVpS0.21
TBVpS0.21
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -47.86%
ROE -633.21%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-49.09%
ROA(5y)-109.27%
ROE(3y)-99.62%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity 1
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 118.3%
Cap/Sales 25.4%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.61
Quick Ratio 1.61
Altman-Z -4.95
F-Score4
WACC9.59%
ROIC/WACCN/A
Cap/Depr(3y)125.73%
Cap/Depr(5y)129.45%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)36.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%25%
EPS Next Y34.35%
EPS Next 2Y24.8%
EPS Next 3Y20.55%
EPS Next 5Y23.6%
Revenue 1Y (TTM)184.04%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%214.32%
Revenue Next Year233.18%
Revenue Next 2Y29.68%
Revenue Next 3Y37.19%
Revenue Next 5Y150.92%
EBIT growth 1Y32.91%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year43.82%
EBIT Next 3Y6.19%
EBIT Next 5YN/A
FCF growth 1Y37.03%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y38.41%
OCF growth 3YN/A
OCF growth 5YN/A